Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial

医学 泊马度胺 来那度胺 内科学 耐受性 多发性骨髓瘤 中性粒细胞减少症 不利影响 地塞米松 耐火材料(行星科学) 肿瘤科 发热性中性粒细胞减少症 胃肠病学 毒性 物理 天体生物学
作者
Suzanne Trudel,Arleigh McCurdy,Martha L Louzada,Stephen Parkin,Darrell White,Michael P. Chu,Rami Kotb,Hira Mian,I. Othman,Jiandong Su,Asher Khan,Engin Gul,Alissa Visram
出处
期刊:Nature Medicine [Nature Portfolio]
标识
DOI:10.1038/s41591-023-02703-y
摘要

Due to evolving treatment standards for newly diagnosed multiple myeloma, many patients will be triple-class exposed after initial relapses and have poor survival. Novel therapies and combinations are therefore required to improve outcomes. B cell maturation antigen (BCMA)-targeted biologics have emerged as an important new area of therapeutics for relapsed multiple myeloma. The two-part ALGONQUIN trial evaluated various doses and schedules of the anti-BCMA antibody-drug conjugate belantamab mafodotin plus pomalidomide and dexamethasone for patients who are lenalidomide refractory and proteosome inhibitor exposed. The primary endpoints, including evaluating dose-limiting toxicities, establishing the recommended Part 2 dose (RP2D) and overall response rate for patients treated at the RP2D, were met. Secondary efficacy endpoints included progression-free survival and overall survival. Patients treated on study (N = 87) had a median of three previous regimens and 55.2% were triple-class refractory. At the RP2D the most common adverse events were decrease in best-corrected visual acuity (71.1%), keratopathy (65.8%), fatigue (57.9%), infection (47.4%; 7.9% grade ≥3), neutropenia (39.5%) and thrombocytopenia (39.5%). For RP2D patients (n = 38), the overall response rate was 85.3%, ≥very good partial response 75.7% and estimated two-year progression-free survival 52.8% (95% confidence interval, 33.9% to 82.4%), at a median follow-up of 13.9 months. The RP2D schedule was associated with manageable antibody-drug conjugate-associated corneal adverse events and improved tolerability without compromising efficacy. Belantamab mafodotin plus pomalidomide and dexamethasone induced durable responses with promising overall survival in relapsed multiple myeloma, the results of which are yet to be confirmed in the phase 3 DREAMM-8 study. ClinicalTrials.gov Identifier: NCT03715478 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LL发布了新的文献求助10
刚刚
Charming发布了新的文献求助10
刚刚
会撒娇的面包完成签到,获得积分10
1秒前
Makoto1377发布了新的文献求助10
2秒前
从此发布了新的文献求助10
2秒前
2秒前
3秒前
赘婿的应助被ki采纳,获得10
3秒前
同心源完成签到 ,获得积分20
4秒前
盗梦师完成签到 ,获得积分10
4秒前
8秒前
故渊丶发布了新的文献求助10
8秒前
li完成签到 ,获得积分10
8秒前
O耶完成签到,获得积分10
8秒前
香蕉觅云的应助被周周采纳,获得30
8秒前
8秒前
英俊的铭的应助被kjh采纳,获得10
9秒前
10秒前
秋风的应助被科研辣鸡采纳,获得10
10秒前
15秒前
12345发布了新的文献求助10
15秒前
共享精神的应助被搞怪的乐荷采纳,获得10
15秒前
16秒前
16秒前
16秒前
kk子的应助被Glllll采纳,获得20
16秒前
浮云客发布了新的文献求助10
16秒前
赤道永恒完成签到,获得积分10
18秒前
18秒前
19秒前
19秒前
霍霍发顶刊完成签到 ,获得积分10
19秒前
大个的应助被科研通管家采纳,获得10
19秒前
19秒前
19秒前
Jasper的应助被葡萄小伊ovo采纳,获得10
19秒前
19秒前
852的应助被葡萄小伊ovo采纳,获得10
19秒前
茉莉雨的应助被科研通管家采纳,获得10
20秒前
天天快乐的应助被葡萄小伊ovo采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183601
求助须知:如何正确求助?哪些是违规求助? 9572875
关于积分的说明 21827816
捐赠科研通 7780716
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558197
邀请新用户注册赠送积分活动 2480485